Back
Akebia Therapeutics 10K Form
Buy
66
AKBA
Akebia Therapeutics
Last Price:
1.86
Seasonality Move:
32.87%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
10K form not available
Receive AKBA News And Ratings
See the #1 stock for the next 7 days that we like better than AKBA
AKBA Financial Statistics
Sales & Book Value
Annual Sales: | $194.62M |
---|---|
Cash Flow: | $-10.1M |
Price / Cash Flow: | 0 |
Annual Sales: | $-0.16 |
Price / Book: | 0 |
Profitability
EPS (TTM): | -0.20680 |
---|---|
Net Income (TTM): | $-40.44M |
Gross Margin: | $120.47M |
Return on Equity: | 0% |
Return on Assets: | -17.19% |
Akebia Therapeutics Earnings Forecast
Key Akebia Therapeutics Financial Ratios
- The Gross Profit Margin over the past 11 years for AKBA is 61.90%.
- The Selling, General & Administrative Expenses for AKBA have been equal to 51.50% of Gross Profit Margin.
- The Research & Development expenses have been 32.41% of Revenue.
- The Interest Expense is -11.62% of Operating Income.
- The Net Earning history of AKBA is -26.68% of Total Revenues.
- Per Share Earnings over the last 12 years have been positive in 6 years.
Akebia Therapeutics Stock Price Chart
Industry, Sector and Symbol
Stock Exchange: | NASDAQ |
---|---|
Industry: | Biotechnology |
Sector: | Health Care |
Current Symbol: | AKBA |
CUSIP: | 00972D |
Website: | akebia.com |
Debt
Debt-to-Equity Ratio: | -1.13 |
---|---|
Current Ratio: | 1.04 |
Quick Ratio: | 0.65 |
Price-to-Earnings
Trailing P/E Ratio: | 0 |
---|---|
Forward P/E Ratio: | 0 |
AKBA Technical Analysis vs Fundamental Analysis
Buy
66
Akebia Therapeutics (AKBA)
is a Buy
Is Akebia Therapeutics a Buy or a Sell?
-
Akebia Therapeutics stock is rated a Buy
The current Akebia Therapeutics [AKBA] share price is $1.86. The Score for AKBA is 66, which is 32% above its historic median score of 50, and infers lower risk than normal.